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Stress-induced increases in neonatal corticosterone demonstrate a unique shift from 
ACTH independence to ACTH dependence between postnatal day 2 (PD2) and day 
8 (PD8) in newborn rats. This shift could be due to the binding of a bioactive, non- 
immunoreactive plasma ligand to the adrenocortical melanocortin 2 receptor (MC2R) 
(ACTH receptor). A potent MC2R antagonist would be useful to evaluate this phenom-
enon in the neonate. Therefore, we investigated the acute corticosterone response 
to ACTH(1–39) injection in rat pups pretreated with newly developed MC2R antagonists 
(GPS1573 and GPS1574), which have not been tested in vivo. The doses used in vivo 
were based on their in vitro potency, with GP1573 being more potent than GPS1574. 
GPS1573 (PD2 and PD8), GPS1574 (PD2 only), or vehicle were injected intraperitoneally 
(ip) 10 min before baseline sampling. Then, 0.001 mg/kg of ACTH(1–39) was injected ip, 
and subsequent blood samples obtained for the measurement of plasma corticosterone. 
Pretreatment of PD2 pups with GPS1573 demonstrated augmentation, rather than inhi-
bition, of the corticosterone response to ACTH. In PD8 pups, pretreatment with 0.1 mg/
kg GPS1573, but not 4  mg/kg, augmented the corticosterone response to ACTH. 
Pretreatment with GPS1574 attenuated the plasma corticosterone response to ACTH 
at 30 min in PD2 pups. The activity of these two compounds in vivo do not match their 
potency in vitro, with GPS1573 leading to a small augmentation of the corticosterone 
response to ACTH in vivo while GPS1574 resulted in inhibition.
Keywords: acTh, Mc2r, corticosterone, adrenal cortex, antagonist
inTrODUcTiOn
Development of the neonatal hypothalamic–pituitary–adrenal (HPA) axis is critical for normal matu-
ration of the lung, closing of the patent ductus arteriosus, and improving vasoconstrictor responses to 
catecholamines, as well as for stress-induced increases in blood glucose and blood pressure (1–3). In 
light of the increasing rate of premature births in the United States, it is important to understand the 
mechanisms of steroidogenesis and HPA axis maturation in the premature and full-term neonate (4). 
The neonatal rat model of human prematurity serves as a useful tool in studying the development of 
the HPA axis because the rat is an altricial animal. The full-term, newborn rat is immature compared 
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to a full-term human neonate (5, 6). The primary glucocorticoid 
in the neonatal rat, corticosterone, is secreted from the zona 
fasciculata of the adrenal cortex in response to ACTH binding 
and activation of the melanocortin 2 receptor (MC2R) (7, 8). The 
binding of ACTH to MC2R leads to an increase in intracellular 
cyclic adenosine monophosphate (cAMP), causing activation of 
protein kinase A (PKA), and subsequent increase in movement 
of free cholesterol across the mitochondrial membrane into the 
cytosol (7–10). This transport of free cholesterol, mediated by the 
steroidogenic acute regulatory protein (StAR), is the rate-limiting 
step of steroidogenesis (11).
We have previously shown that on postnatal day 2 (PD2), rat 
pups exposed to hypoxic stress demonstrate an increase in cor-
ticosterone without an appreciable increase in immunoassayable 
ACTH and adrenal cAMP (12, 13). This phenomenon could be 
due to larger posttranslational products of POMC activating the 
MC2R receptor (14), which are not necessarily detected in our 
ACTH immunoassay. Although difficult to study without com-
pletely eliminating potential confounders, there are data suggest-
ing that premature infants born at <32 weeks can mount a cortisol 
response without the large increase in plasma ACTH found in 
infants born >32 weeks gestational age (15). As stated earlier, the 
newborn rat is useful as a model of human prematurity (5, 6).
By postnatal day 8 (PD8), pups show an increase in corticos-
terone with the classic increase in immunoassayable ACTH and 
adrenal cAMP (12, 13, 16). The ability of the PD2 adrenal gland 
to respond to stress without a detectable increase in immunore-
active ACTH could be due to a bioactive, non-immunoreactive 
form of ACTH or another POMC product that can bind to and 
activate the adrenocortical MC2R. If the corticosterone response 
to stress in PD2 pups can be blocked by antagonizing the MC2R, 
it would suggest that a bioactive form of ACTH (not measured 
by immunoassay) is working through the MC2R in PD2 pups.
GPS1573 (Nle-P-f-R-w-F-K-A-V-G-K-K-R-R NH2) and 
GPS1574 [Nle-(E-f-R-w-F-K)-A-V-G-K-K-R-R NH2] are newly 
described, potent (IC50 = 66 ± 23 and 260 ± 1 nM, respectively), 
and dose-dependent antagonists of ACTH-stimulated MC2R 
activity in  vitro (17). Note that the structures of the two com-
pounds are similar except that GPS1574 has a ring structure. 
However, they have not been studied in vivo. The primary goal 
of the present study is to investigate the effect of GPS1573 and 
GPS1574 in  vitro (adrenal cells) and in  vivo (neonatal rats) 
in order to set the stage for its use in evaluating the role of 
endogenous ACTH in the neonatal adrenal stress response. We 
hypothesize that these MC2R antagonists are effective in adrenal 
cells from neonatal rats in  vitro. Furthermore, we hypothesize 
that in the neonatal rat, GPS1573 and GPS1574, when given at 
a 100- to 4000-fold higher dose and 4000- to 8000-fold higher 
dose, respectively, than exogenous ACTH(1–39), will attenuate the 
adrenocortical corticosterone response to ACTH.
MaTerials anD MeThODs
animal Treatment and experimental 
Protocol
The animal protocol was approved by the Institutional Animal 
Care and Use Committee of Aurora Health Care. Timed-pregnant 
Sprague-Dawley rats at 14–17 gestational days (N =  45) were 
obtained from Harlan Sprague Dawley (Indianapolis, IN, USA), 
maintained on a standard diet, and had water available ad libitum 
in a controlled environment (0600–1800 hours lights on). Dams 
were allowed to deliver and care for their pups without interfer-
ence until experimentation. The MC2R antagonists GPS1573 
and GPS1574 were synthesized by Genepep (St. Jean de Védas, 
France) and reconstituted, as described previously (17).
adrenal cell Preparation and gPs1573 
and gPs1574 In Vitro
Adrenal cells from rats (N = 11 adults, 46 PD2 pups, and 26 PD8 
pups) were dispersed and studied as previously described (18, 19). 
Briefly, rats were killed by decapitation, and both adrenal glands 
were removed and cleaned of surrounding fat. Only adult adrenal 
glands were decapsulated prior to cell dispersion. After a 90-min 
type I collagenase treatment and washing, viable cells were plated 
in a 96-well microtiter plate (10,000 cells/well) and pretreated for 
1 h with (a) no antagonist (b) 750 nM GPS1573, or (c) 750-nM 
GPS1574 at 37°C in 10% CO2 (balance room air). After pretreat-
ment, rat ACTH(1–39) (Bachem) was added to cell suspensions at 
appropriate concentrations and incubated for 1 h. Medium was 
removed and immediately assayed for corticosterone (20).
gPs1573 and gPs1574 studies in the 
neonatal rat In Vivo
Rat pups were randomly assigned to experimental groups on the 
morning of the experiment. Then, rat pups were removed from 
the dams and placed in a small cage with adequate bedding, 
where they were allowed free range of motion and room to hud-
dle. A variable control heating pad (Moore Medical, Farmington, 
CT, USA) was placed beneath the bedding and kept at the lowest 
setting required to maintain body temperature in normoxic rats 
at these ages (13, 21). After 10 min, rat pups were removed from 
the cage and quickly weighed.
In the GPS1573 studies, pups (both sexes; N = 252) were stud-
ied at PD2 (N = 96) and PD8 (N = 156) because these ages span 
the critical time during which the neonatal rat’s adrenal response 
to hypoxia shifts from immunoreactive ACTH independent to 
ACTH dependent (13, 16). Pups were injected intraperitoneally 
(ip) with either vehicle (10 μl/kg body wt of isotonic saline) or 
GPS1573 (diluted in isotonic saline) in low or high dose (0.1 or 
4.0 mg/kg body wt, respectively). We chose to give GPS1573 ip 
because (a) it is a small peptide amenable to proper absorption 
by this route, (b) ACTH injections given ip are effective, and 
(c) subcutaneous injection was ineffective (data not shown).
In the GPS1574 studies, pups (both sexes, N = 42) were only 
studied at PD2, with the 60-min time point omitted because 
of drug’s limited supply, the data from the 60-min time point 
with GPS1573 described above, higher necessary dose based 
on the in vitro studies [current experiments and Ref. (17)], and 
its expense. GPS1574 was given at a dose of 4 or 8  mg/kg ip. 
Otherwise, the experiments were performed as described for 
GPS1573.
Ten minutes after GPS1573 or GPS1574 injection, a subset 
of pups was quickly decapitated and trunk blood was collected 
(baseline, time 0). Immediately after the baseline collection, 
FigUre 1 | corticosterone responses to acTh in vitro in adrenal cells from rats of different ages. Cells were pretreated with vehicle, GPS1573, or 
GPS1574 (750 nM). Each point is the mean of two replicates.
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1  μg/kg (0.001  mg/kg) of porcine ACTH (Sigma Chemical, 
St. Louis, MO, USA) was injected ip, as described (22–24). Subsets 
of pups were decapitated at 15, 30, or 60  min (GPS1573 only) 
post-injection. In another group of pups (N = 163), the vehicle 
for ACTH injection (isotonic saline) was injected ip 10 min after 
GPS1573 or GPS1574 administration, and blood collected as 
described above. Trunk blood was collected in EDTA tubes (1 pup/
sample), processed to plasma, and stored frozen (−20°C). Plasma 
corticosterone was measured by immunoassay, as described 
previously (MP Biomedicals, Orangeburg, NJ, USA) (25).
statistical analyses
Corticosterone data were analyzed by two-way ANOVA. Post hoc 
analysis was performed by Holm–Sidak multiple range test 
(P < 0.05) (SigmaPlot 11.0). Data are presented as mean ± SEM.
resUlTs
gPs1573 and gPs1574 In Vitro
Figure 1 shows the corticosterone response to ACTH in dispersed 
adrenal cells of rat pups (PD2 and PD8) and adults treated with 
GPS1573 and GPS1574. The cells from adult adrenal glands 
showed significant inhibition of the corticosterone response to 
ACTH in vitro, with GPS1573 being more potent than GPS1574. 
A similar response was observed in PD2 pup adrenal cells, as 
previously described for adult rats (17). In PD8 pup adrenal cells, 
however, there was equivalent inhibition between GPS1573 and 
GPS1574, compared to vehicle control.
gPs1573 In Vivo
The plasma corticosterone responses to exogenous ACTH in 
PD2 pups pretreated with either vehicle (for GPS1573) or the 
low or high dose of GPS1573 are shown in Figure 2. Baseline 
plasma corticosterone responses (10  min after injection of 
GPS1573) ranged from 30.4 ±  3.7 to 45.7 ±  8.7  ng/ml and 
were not different from our previously published baseline 
data without an injection 10  min before sampling (23, 24). 
PD2 pups pretreated with vehicle did not show an increase in 
corticosterone in response to ACTH at 15 min but did have an 
increase in corticosterone at 30 min (166.0 ± 17.1 ng/ml) and 
60 min (137.2 ± 43.5 ng/ml). After pretreatment with the low 
dose of GPS1573, compared to vehicle, the PD2 pups showed 
a significantly augmented plasma corticosterone response at 
15 min (67.8 ±  7.9 ng/ml) and 60 min (200.0 ±  23.6 ng/ml). 
When pretreated with the high dose of GPS1573, PD2 pups 
demonstrate an even greater augmentation of the corticosterone 
response at 15  min (115.5 ±  11.0  ng/ml), when compared to 
pretreatment with low dose or vehicle.
The plasma corticosterone responses to exogenous ACTH in 
PD8 pups pretreated with either vehicle (for GPS1573) or the low 
or high dose of GPS1573 are shown in Figure 3. Baseline plasma 
corticosterone responses (10  min after injection of GPS1573) 
ranged from 22.8 ± 3.7 to 25.7 ± 2.9 ng/ml and were not different 
from our previously published baseline data, without an injec-
tion 10 min before sampling (23, 24). The plasma corticosterone 
response to ACTH in PD8 pups was less than PD2 pups. In fact, 
there was no significant increase in corticosterone in response to 
ACTH in PD8 pups. Compared to vehicle, PD8 pups pretreated 
with the low dose of GPS1573 showed an augmentation of the 
plasma corticosterone response to ACTH at 15 min (45.8 ± 2.6  
ng/ml), 30 min (54.5 ± 3.7 ng/ml), and 60 min (50.4 ± 6.5 ng/ml). 
The corticosterone response to ACTH in PD8 pups pretreated 
with the high dose of GPS1573 was not different than vehicle at 
15 min (34.3 ± 4.5 ng/ml) and 30 min (36.0 ± 6.0 ng/ml) but was 
less than the low dose of GPS1573 at 60 min (40.4 ± 5.9 ng/ml).
We also evaluated a time control in which pups were pretreated 
with GPS1573 and then injected with vehicle for ACTH (Table 1). 
For the most part, there were no statistically significant changes in 
plasma corticosterone. It is important to note that baseline plasma 
corticosterone concentrations were similar to those in our prior 
studies without ip injection prior to baseline (23, 24). However, 
there was a small increase in plasma corticosterone at 15  min 
in PD2 pups pretreated with the high dose of GPS1573 and at 
30 min in PD8 pups pretreated with the low dose of GPS1573.
FigUre 3 | Plasma corticosterone response to acTh injection in 
postnatal 8 (PD8) rats pretreated with the low and high doses of 
gPs1573. PD8 pups were injected with vehicle and low or high dose of 
GPS1573 (0.1 or 4.0 mg/kg body wt ip, respectively). Ten minutes later, 
baseline samples were obtained, and then porcine ACTH (0.001 mg/kg) was 
injected ip. aSignificantly different from baseline (0 min). bSignificantly different 
from vehicle (P < 0.05). cSignificantly different from 4.0 mg/kg. Data are 
presented as means ± SE. Note the y-axis range is lower than Figure 2 
(PD2 pups). N values (number of pups) for each mean are shown in the 
figure label.
FigUre 2 | Plasma corticosterone response to acTh injection in 
postnatal 2 (PD2) rats pretreated with the low and high doses of 
gPs1573. PD2 pups were injected with vehicle and low or high dose of 
GPS1573 (0.1 or 4.0 mg/kg body wt ip, respectively). Ten minutes later, 
baseline samples were obtained, and then porcine ACTH (0.001 mg/kg) was 
injected ip. aSignificantly different from baseline (0 min). bSignificantly different 
from vehicle (P < 0.05). Data are presented as means ± SE. N values 
(number of pups) for each mean are shown in the figure label.
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gPs1574 In Vivo
Although we originally planned to only evaluate GPS1573 because 
of its higher potency in vitro (17), which was confirmed by our 
in  vitro studies, the lack of inhibition with GPS1573 described 
above led us to do a limited number of new in vivo experiments 
with the apparently less potent GPS1574. We limited the GPS1574 
study to PD2 (an age we are most interested in) through 30 min 
because of the need to use a higher dose of this very expensive 
drug, which was in limited supply and because the peak response 
to ACTH injection was at 30 min. As Figure 4 demonstrates, there 
was no inhibition at 15 min after ACTH administration, but a dose-
dependent inhibition at 30 min was seen after ACTH injection. 
The time control for GPS1574 (saline injection rather than ACTH) 
did not reveal any changes in corticosterone (data not shown) and 
had baseline serum corticosterone concentrations similar to our 
previous studies without injection before baseline sampling.
DiscUssiOn
This study evaluated the corticosterone response to exogenous 
ACTH injection in neonatal rats pretreated with potent, in vitro 
MC2R antagonists, which have not previously been tested in vivo 
(17). We hypothesized that these compounds would attenuate the 
adrenocortical MC2R, thereby resulting in a lower corticosterone 
response to ACTH in PD2 and PD8 rats. If these antagonists were 
effective in vivo, it would allow us to evaluate the possibility that 
stress-induced increases in corticosterone at PD2 that are inde-
pendent of increases in immunoreactive plasma ACTH could be 
explained by binding of a non-immunoreactive corticotrophic 
ligand to the adrenocortical MC2R (12, 13, 16, 21). We chose to 
study neonatal rats based on previous studies (23, 24). Additionally, 
we are currently unable to study these compounds in adult rats 
because of the very large quantities of the GPS compounds needed, 
the compounds’ expense, and their limited supply.
Although the limited GPS1574 in vivo studies were performed 
after the responses to GPS1573 were ascertained, we will first 
discuss the GPS1574 data. GPS1574 resulted in an attenuated 
corticosterone response at 30  min after ACTH injection. We 
studied GPS1574 at a dose 4000- and 8000-fold higher than the 
exogenous ACTH dose. We were unable to use an even higher 
dose because of the limited supply of this compound. With the 
assumption that these GPS compounds are absorbed in a manner 
similar to ACTH, we calculated the plasma concentration of the 
GPS compounds to be at least 10- to 20-fold higher than the peak 
plasma ACTH concentration after injection. It is possible that 
these drugs are not as well absorbed as ACTH(1–39) and/or that 
they are metabolized much more readily than ACTH(1–39), perhaps 
requiring even higher doses ip. These preliminary results show 
promise for a more comprehensive analysis of this compound at 
much higher doses.
GPS1573, given in vivo at a 4000-fold higher dose of exog-
enous ACTH, did not antagonize the adrenal response to ACTH 
at either age. Rather, we demonstrated that pretreatment with 
GPS1573 augmented the corticosterone response to ACTH 
stimulation in  vivo. In PD2 pups, the low dose of GPS1573 
significantly augmented the corticosterone response to ACTH 
at 15 and 60 min compared to vehicle while the high dose dem-
onstrated an even greater augmentation at 15 min compared to 
FigUre 4 | Plasma corticosterone response to acTh injection in 
postnatal 2 (PD2) rats pretreated with gPs1574. Pups were injected with 
vehicle or GPS1574 (4 or 8 mg/kg body wt ip, respectively). Ten minutes 
later, baseline samples were obtained, and then porcine ACTH (0.001 mg/kg) 
was injected ip. aSignificantly different from baseline (0 min). bSignificantly 
different from vehicle (P < 0.05). Data are presented as means ± SE. 
N values (number of pups) for each mean are shown in the figure label.
TaBle 1 | Plasma corticosterone (nanogram per milliliter) response to vehicle (for acTh injections) after pretreatment of PD2 and PD8 pups with the 
low dose (0.1 μg/kg) or high dose (4 μg/kg) of gPs1573.
age Dose Time (min)
Baseline 15 30 60
PD2 Low (N = 5–6) 25.7 ± 7.0 49.4 ± 16.6 37.1 ± 10.3 42.0 ± 7.7
High (N = 7) 41.0 ± 9.6 67.4 ± 6.2a 25.4 ± 4.9 29.0 ± 9.4
PD8 Low (N = 5) 17.0 ± 4.1 24.6 ± 3.4 41.2 ± 4.4a,b 30.3 ± 11.5
High (N = 11–12) 16.4 ± 2.6 21.0 ± 3.2 14.5 ± 3.2 15.7 ± 2.9
aDifferent from baseline.
bDifferent from high dose within PD8.
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vehicle and low dose. In PD8 pups, pretreatment with the low 
dose of GPS1573 showed significant augmentation compared to 
vehicle at 60 min while pretreatment with the high dose showed 
no significant increase in corticosterone at any time point. 
GPS1573 did not consistently act as an agonist per se, with only 
small increases in corticosterone in response to ACTH vehicle 
(saline) at two time points.
This leads us to conclude that although GPS1573 acts as a com-
petitive antagonist in vitro in adrenal cells from PD2, PD8, and 
adult cells, pretreatment with it in vivo results in an augmentation 
of the response to the natural ligand for the MC2R (ACTH). A 
similar phenomenon has been shown for nuclear (intracellular) 
receptors (26).
What could explain the effect demonstrated for a G-protein 
coupled receptor like the MC2R? First, it could be that the IC50 
of GPS1573 is too high to be effective in vivo, despite the fact that 
we gave it at a 4000-fold higher dose than ACTH. The data from 
GPS1574 do not corroborate this notion since it has a higher IC50 
in vitro but was effective in vivo. It is also possible that GPS1573 
acts as an antagonist in  vitro but is a biasing agonist in  vivo. 
That is, in  vivo, rather than blocking the receptor, it actually 
augments G-protein coupled transduction when ACTH binds 
to the MC2R (27, 28). This phenomenon could also be attribut-
able to GPS1573 triggering a non-specific sympathetic nervous 
system-induced increase in the sensitivity of the adrenal cortex 
to ACTH (22, 29–36). Another possibility is that GPS1573 is 
inactivated shortly after being injected or that it has a very short 
half-life in vivo.
Potential drawbacks of our study design include the route of 
administration of GPS1573 and GPS1574. We chose ip adminis-
tration a priori, since these antagonists are small compounds, and 
we have previously shown that ip ACTH injection is effective in 
stimulating corticosteronogenesis (22–24). We performed a few 
pilot studies with subcutaneous injection, which were ineffective 
(data not shown). However, an alternate route of administration 
(e.g., intravenous or intramuscular) may be more effective. It is 
also possible that these compounds would have been more effec-
tive in vivo in postpubertal rats. Alternate controllers of neonatal 
steroidogenesis, including postganglionic sympathetic input 
described above, have been proposed; however, the current study 
avoids these confounders by injecting ACTH rather than using 
stress as a stimulus to ACTH (22–24).
In conclusion, it appears that high dose of GPS1574 has 
potential as a competitive antagonist of ACTH in vivo. However, 
GPS1573 seems to act like a biasing agonist in vivo when given 
before an ACTH injection even though it is not consistently an 
agonist when given alone. The differences in behavior between 
these two compounds in vivo may be related to the ring structure 
of GPS1574.
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